Publication
Abstract
A randomized, double-blind, placebo-controlled, multi-center phase III study of RAD001 adjuvant therapy in poor risk patients with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 versus matching placebo after patients have achieved complete remission with first-line rituximab-chemotherapy